See what's happening in the market right now with MarketBeat's real-time news feed. Aquestive Therapeutics Inc has risen higher in 1 of those 2 years over the subsequent 52 week period, corresponding to a historical probability of 50 %. Their forecasts range from $7.00 to $33.00. No recent news for Aquestive Therapeutics Inc. (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. Counsel, Chief Compliance Officer & Corp. Sec. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. CNN Sans™ & © 2016 Cable News Network. About the Aquestive Therapeutics, Inc. stock forecast Unlock SECRET Features HERE for … Aquestive Therapeutics, Inc. Common Stock (AQST) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Since then, AQST shares have increased by 55.8% and is now trading at $4.58. This suggests a possible upside of 236.9% from the stock's current price. This suggests a possible upside of 242.1% from the stock's current price. Aquestive Therapeutics Inc Stock Price Forecast, "AQST" Predictons for2021 View the latest AQST financial statements, income statements and financial ratios. One share of AQST stock can currently be purchased for approximately $4.58. Annual stock financials by MarketWatch. Get Aquestive Therapeutics Inc (AQST:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View analysts' price targets for Aquestive Therapeutics or view top-rated stocks among Wall Street analysts. Find real-time ACST - Acasti Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. View Aquestive Therapeutics' earnings history. View which stocks have … The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. Acasti Pharma Inc. NASDAQ Updated Feb 24, 2021 7:35 PM ACST 0.82 0.08 (11.13%). Learn about financial terms, types of investments, trading strategies and more. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Top institutional investors include BlackRock Inc. (3.88%), Nuveen Asset Management LLC (1.58%), Renaissance Technologies LLC (0.81%), Northern Trust Corp (0.67%), Bank of New York Mellon Corp (0.27%) and Nisa Investment Advisors LLC (0.19%). Receive a free world-class investing education from MarketBeat. Since then, AQST stock has increased by 79.9% and is now trading at $5.29. You may vote once every thirty days. The consensus price target for the stock as assigned by Wall Street analysts is $15, meaning bulls need an upside of 180.37% from its current market value. 3 Wall Street analysts that have issued a 1 year AQST price target, the average AQST price target is $17.67, with the highest AQST stock price forecast at $32.00 and the lowest AQST stock price forecast at $7.00. A Warner Media Company. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.03. MarketBeat's community ratings are surveys of what our community members think about Aquestive Therapeutics and other stocks. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Daniel Barber, James S Scibetta, Keith J Kendall, Lori J Braender, Peter E Boyd, and Theresa Wood. The price has fallen in 6 of the last 10 days and is down by -17.89% for this period. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. It also develops APL-130277, a sublingual film formulation of apomorphine to treat Parkinson's disease. View institutional ownership trends for Aquestive Therapeutics. Get short term trading ideas from the MarketBeat Idea Engine. The average price target represents a 402.18% increase from the last price of $4.58. View our earnings forecast for Aquestive Therapeutics. Fundamental company data provided by Zacks Investment Research. There are currently 5 buy ratings for the stock. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment, Aquestive Therapeutics Provides Business Update. Aquestive Therapeutics has received 50.76% “outperform” votes from our community. 59.15% of the stock of Aquestive Therapeutics is held by institutions. During the day the stock fluctuated 3.53% from a day low at $5.38 to a day high of $5.57. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Aquestive Therapeutics has a market capitalization of $153.98 million and generates $52.61 million in revenue each year. 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. NasdaqGM:AQST Earnings and Revenue Growth November 9th 2020 Taking a look at the bigger picture now, one of the ways we can understand these forecasts is … Now that they have an approval coming up on the second, I expect them to perform phenomenally for the rest of... 3 2 Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. All rights reserved. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Over the next 52 weeks, Aquestive Therapeutics Inc has on average historically risen by 9 % based on the past 2 years of stock performance. Aquestive Therapeutics price target lowered to $7 from $10 at Lake Street ... AQST-108 achieved a similar time to maximal concentrations, or median Tmax, when compared to both the subcutaneous and intramuscular injections of epinephrine. Vote “Outperform” if you believe AQST will outperform the S&P 500 over the long term. Your current $100 investment may be up to $272.87 in 2026. Company insiders that have sold Aquestive Therapeutics company stock in the last year include Alexander Mark Schobel, John T Maxwell, and Keith J Kendall. Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. ACST - Acasti Pharma Inc Stock quote - CNNMoney.com Markets Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. According to analyst projections, AQST’s forecast low is $7 with $32 as the target high. On average, they anticipate Acasti Pharma's stock price to reach $2.81 in the next year. The 12-month stock price forecast is 15.00, which is an increase of 171.00% from the latest price. Learn more. Aquestive Therapeutics does not currently pay a dividend. The P/E ratio of Aquestive Therapeutics is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Aquestive Therapeutics Inc quote is equal to 5.635 USD at 2021-02-21. Based on an average daily volume of 794,700 shares, the days-to-cover ratio is presently 1.7 days. Aquestive Therapeutics saw a drop in short interest during the month of January. On average, they expect Aquestive Therapeutics' share price to reach $15.67 in the next year. With a 5-year investment, the revenue is expected to be around +172.87%. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. Should I Buy Aquestive Therapeutics, Inc. (AQST)? The average price target is $23.00 with a high forecast of $32.00 and a low forecast of $14.00. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Based on our forecasts, a long-term increase is expected, the "AQST" stock price prognosis for 2026-02-13 is 15.376 USD. In the medium term (3months), AQST's stock price should outperform the … View Aquestive Therapeutics, Inc. AQST investment & stock information. Would Shareholders Who Purchased Aquestive Therapeutics' (NASDAQ:AQST) Stock Year Be Happy With The Share price Today? Most stock quote data provided by BATS. Aquestive Therapeutics employs 232 workers across the globe. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference, Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization, Why Aquestive Therapeutics Stock Is Trading Higher Today, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Compare Top Brokerages Here. Learn everything you need to know about successful options trading with this three-part video course. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. 5 brokers have issued 12 month price objectives for Acasti Pharma's stock. To see all exchange delays and terms of use please see disclaimer. Vote “Underperform” if you believe AQST will underperform the S&P 500 over the long term. AQST - Aquestive Therapeutics Inc Stock quote - CNNMoney.com Markets Find the latest Aquestive Therapeutics, Inc. (AQST) stock quote, history, news and other vital information to help you with your stock trading and investing. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. As of January 29th, there was short interest totaling 1,370,000 shares, a drop of 29.7% from the January 14th total of 1,950,000 shares. Get the latest Aquestive Therapeutics, Inc. AQST detailed stock quotes, stock … Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. (Add your “outperform” vote. AQST Stock Analysis Overview What this means: Aquestive Therapeutics Inc (AQST) gets an Overall Rank of 55, which is an above average rank under InvestorsObserver's stock ranking system. View all of AQST's competitors. Aquestive Therapeutics does not have a long track record of dividend growth. Aquestive Therapeutics' management team includes the following people: Sr. VP, Gen. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its earnings results on Monday, November, 9th. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. MarketBeat just released five new trading ideas, but Aquestive Therapeutics wasn't one of them. AQST: Aquestive Therapeutics, Inc. - Price and Consensus Chart. In the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. According to . Interested parties can register for or listen to the call using this link or dial in at Not Available. The company had revenue of $8.26 million for the quarter, compared to analysts' expectations of $8.52 million. View which stocks have been most impacted by COVID-19. © 2020 Cable News Network. Revenue vs Market: AQST's revenue (37.9% per year) is forecast to grow faster than the US market (10.7% per year). Sr. VP of Bus. Aquestive Therapeutics is headquartered at 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics: Back From The Brink, ~57% Upside Potential In New Asset Structuring, Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer. Want to see which stocks are moving? High Growth Revenue : AQST's revenue (37.9% per year) is forecast … Earnings for Aquestive Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.20) per share. Detailed list of analyst forecasts Find real-time AQST - Aquestive Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Export data to Excel for your own analysis. The consensus among Wall Street equities research analysts is that investors should "buy" Aquestive Therapeutics stock. 5 brokerages have issued 12-month price objectives for Aquestive Therapeutics' stock. Aquestive Therapeutics, Inc. NASDAQ Updated Feb 24, 2021 12:58 AM AQST 5.27 0.14 (2.59%). The consensus price target for the stock as assigned by Wall Street analysts is $15, meaning bulls need an upside of 116.76% from its current market value. Aquestive Therapeutics Inc. Aquestive Therapeutics fell from $8 to $4 in September 2020, and I think they could pull back eventually, regardless of press releases. Aquestive Therapeutics has received 167 “outperform” votes. View analyst ratings for Aquestive Therapeutics or view top-rated stocks. All Rights Reserved. Aquestive Therapeutics has only been the subject of 1 research reports in the past 90 days. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. AQST stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Renaissance Technologies LLC, Nisa Investment Advisors LLC, Squarepoint Ops LLC, Bank of New York Mellon Corp, BlackRock Inc., JPMorgan Chase & Co., and Financial Advocates Investment Management. A high percentage of insider ownership can be a sign of company health. Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd and Theresa Wood. 30,322 Please log in to your account or sign up in order to add this asset to your watchlist. View insider buying and selling activity for Aquestive Therapeutics or or view top insider-buying stocks. Learn more. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Further, Aquestive Therapeutics, Inc. (AQST) has a beta value of 0, and an average true range (ATR) of 0.44. Identify stocks that meet your criteria using seven unique stock screeners. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021. All times are ET. View our full suite of financial calendars and market data tables, all for free. ... 2021 7:53 p.m. EST Delayed quote … Aquestive Therapeutics will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), OrganiGram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB). Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. According to analysts' consensus price target of $15.67, Aquestive Therapeutics has a forecasted upside of 242.1% from its current price of $4.58. Aquestive Therapeutics has received a consensus rating of Buy. Do Not Sell My Information. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Analysts have given the company’s stock an average 52-week price target of $15, forecast between a low of $7 and high of $32. View Aquestive Therapeutics' Short Interest. Disclaimer. AQST stock forecast Our latest prediction for Aquestive Therapeutics Inc's stock price was made on the Dec. 6, 2018 when the stock price was at 8.75$.. ET by Tomi Kilgore Aquestive Therapeutics shares surge 6.7% in trading debut Get daily stock ideas top-performing Wall Street analysts. Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. As of 2021 February 25, Thursday current price of OGI stock is 3.030$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. OrganiGram Holdings, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame.